EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study

Yijiao Chen, Dexiang Zhu, Yiyi Yu, Wenju Chang, Lechi Ye, Qingyang Feng, Pingping Xu, Miao Chen, Meiling Ji, Ye Wei, Tianshu Liu, Jianmin Xu

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.05.006 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Yijiao Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Department of General Surgery, Zho…. Hauptthemen laut MEDLINE: Bevacizumab, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Colorectal cancers (CRC) with BRAF V600E mutation exhibit limited chemotherapy response and a poor prognosis. Safety and efficacy of the VIC (Vemurafenib/Irinotecan/Cetuximab) regimen in the first-line setting for patients with BRAF V600E-mutated CRC remain undetermined. METHODS: In the prospective cohort study, the untreated, BRAF V600E-mutated, unresectable or metastatic CRC patients were enrolled. The VIC regimen and bevacizumab plus chemotherapy were compared in the first-line setting. The objective response rate (ORR), disease control rate (DCR), conversion resection rate, progression-free survival (PFS), and overall survival (OS) were evaluated. RESULTS: In the intent-to-treat analysis, 38 patients received VIC regimen and 40 received bevacizumab plus chemotherapy. The ORR and DCR in the VIC group were significantly higher than in the bevacizumab-therapy group (ORR: 63.2% vs. 37.5%, P = .025; DCR: 94.7% vs. 75.0%, P = .019). The VIC regimen significantly outperformed bevacizumab plus chemotherapy in both PFS (11.9 vs. 7.7 months; hazard ratio [HR] = 0.51, 95% CI, 0.30-0.87; P = .010) and OS (25.3 vs. 14.6 months; HR = 0.43, 95% CI, 0.22-0.82; P = .011). In the VIC group, the conversion resection rate for liver metastases was 34.8% (8 of 23 patients), and for unresectable local CRC it was 54.5% (6 of 11 patients). The adverse events rates of Grade 3 to 4 were 34.2% and 32.5% for the VIC regimen and bevacizumab plus chemotherapy respectively. CONCLUSIONS: Among Asian patients with BRAF V600E-mutated CRC, the VIC regimen showed favorable outcomes compared to bevacizumab plus chemotherapy in terms of tumor response and oncological survival, with a tolerable and manageable toxicity profile in the first-line setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabProto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsMutationCetuximabIrinotecanHumansMiddle AgedMaleFemaleProspective StudiesAgedAdultProgression-Free SurvivalAsian People

Stichwörter der Autor:innen

BRAF V600E MutationBevacizumabCetuximabColorectal CancerVemurafenib

Substanzen

BevacizumabProto-Oncogene Proteins B-rafBRAF protein, humanCetuximabIrinotecan

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Colorectal Surgery, Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Engineeri…
  • Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Department of General Surgery, Huadong Hospital, Fudan University, Shanghai, China.
  • Department of General Surgery, Huadong Hospital, Fudan University, Shanghai, China.
  • Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: liutianshu1969@126.com.

Zitieren

APA

Chen, Y., Zhu, D., Yu, Y., Chang, W., Ye, L., Feng, Q., Xu, P., Chen, M., Ji, M., Wei, Y., Liu, T., & Xu, J. (2024). VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.05.006

Vancouver

Chen Y, Zhu D, Yu Y, Chang W, Ye L, Feng Q, et al. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.05.006

BibTeX
@article{Chen2024,
  author = {Chen, Yijiao and Zhu, Dexiang and Yu, Yiyi and Chang, Wenju and Ye, Lechi and Feng, Qingyang and Xu, Pingping and Chen, Miao and Ji, Meiling and Wei, Ye and Liu, Tianshu and Xu, Jianmin},
  title = {VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.05.006}
}
Kostenlos starten →